ICU Medical (ICUI) CFO gains stock from PRSU vesting and tax withholding
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ICU Medical Chief Financial Officer Brian Michael Bonnell reported equity award activity involving performance-based and time-based stock units. On March 8, 2026, performance stock units granted on March 8, 2024 were certified at 250% of target, resulting in the acquisition of 71,757 shares of common stock, with no exercise price.
On the same date, 39,667 shares of common stock were disposed of at $132.00 per share to cover tax obligations through share withholding, leaving 64,697 shares directly owned afterward. On March 7, 2026, additional equity awards were settled, including 3,522 shares acquired via derivative exercises and 1,263 shares withheld for taxes, resulting in 32,607 directly owned shares after that date.
Positive
- None.
Negative
- None.
Insider Trade Summary
75,279 shares exercised/converted
Mixed
6 txns
Insider
Bonnell Brian Michael
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Performance Shares | 71,757 | $0.00 | -- |
| Exercise | Common Stock | 71,757 | $0.00 | -- |
| Tax Withholding | Common Stock | 39,667 | $132.00 | $5.24M |
| Exercise | Common Stock | 3,522 | $0.00 | -- |
| Exercise | Common Stock | 3,522 | $0.00 | -- |
| Tax Withholding | Common Stock | 1,263 | $0.00 | -- |
Holdings After Transaction:
Performance Shares — 0 shares (Direct);
Common Stock — 104,364 shares (Direct)
Footnotes (1)
- These securities are Restricted Stock Units. Represents the settlement of performance stock units granted on 3/8/2024. Upon the certification of performance results by the Compensation Committee on 2/11/26, the PRSUs were earned at 250% of target, resulting in the acquisition of the shares reported herein. There is neither a purchase price nor an exercise price for the Restricted Stock Units. One third of the units subject to the award shall vest on each of the first, second, and third anniversaries of the grant date. These are restricted stock units that fully vest 3 years from the grant date. These Securities are Performance-based Restricted Stock Units (PRSU). There is neither a purchase price nor an exercise price for the PRSUs.
FAQ
What insider transaction did ICU Medical (ICUI) report for its CFO?
ICU Medical’s CFO, Brian Michael Bonnell, reported equity award activity involving performance-based and restricted stock units, including the acquisition of 71,757 common shares from performance stock units and related share withholding transactions to cover tax obligations in March 2026.
What is the nature of the equity awards reported by ICU Medical (ICUI) CFO?
The awards include restricted stock units and performance-based restricted stock units (PRSUs). Footnotes state there is neither a purchase price nor an exercise price, and that PRSUs were earned at 250% of target after performance certification by the Compensation Committee.
Do ICU Medical (ICUI) restricted stock units have an exercise price?
No. Footnotes state there is neither a purchase price nor an exercise price for the restricted stock units and performance-based restricted stock units. These units settle into common shares upon vesting or performance certification, rather than requiring cash payment to exercise.